Novo Nordisk’s next-gen weight problems drug outcomes a letdown for traders
CHICAGO — Late-stage outcomes of Novo Nordisk’s weight problems candidate CagriSema recommend the drug is corresponding to Eli Lilly’s Zepbound on security and efficacy, additional knowledge indicating that CagriSema is probably not the standout remedy that traders had hoped for.
Novo beforehand reported that sufferers on CagriSema misplaced 20% of their weight in a 68-week Section 3 trial when taking a look at all contributors, the same stage of weight reduction seen in Zepbound research.
Novo is planning an extended CagriSema examine to see if sufferers can proceed to lose extra weight, however full outcomes launched Sunday present that the speed of weight reduction began to plateau on the finish of 68 weeks, elevating questions round how way more weight sufferers would be capable of lose.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the pharma business — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
